During the last session, Mereo BioPharma Group plc (NASDAQ:MREO)’s traded shares were 3.07 million. At the end of the trading day, the stock’s price was $1.13, reflecting an intraday loss of -6.61% or -$0.08. The 52-week high for the MREO share is $1.85, that puts it down -63.72 from that peak though still a striking 61.95% gain since the share price plummeted to a 52-week low of $0.43. The company’s market capitalization is $141.23M, and the average intraday trading volume over the past 10 days was 2.6 million shares, and the average trade volume was 1.34 million shares over the past three months.
Mereo BioPharma Group plc (MREO) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. MREO has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be $0.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
Mereo BioPharma Group plc (NASDAQ:MREO) trade information
Mereo BioPharma Group plc (MREO) registered a -6.61% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -6.61% in intraday trading to $1.13 this Wednesday, 05/24/23, hitting a weekly high. The stock’s 5-day price performance is -13.74%, and it has moved by 0.89% in 30 days. Based on these gigs, the overall price performance for the year is 116.89%. The short interest in Mereo BioPharma Group plc (NASDAQ:MREO) is 4.23 million shares and it means that shorts have 2.91 day(s) to cover.
The consensus price target of analysts on Wall Street is $4.25, which implies an increase of 73.41% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $4.00 and $5.00 respectively. As a result, MREO is trading at a discount of -342.48% off the target high and -253.98% off the low.
Mereo BioPharma Group plc (MREO) estimates and forecasts
Statistics show that Mereo BioPharma Group plc has outperformed its competitors in share price, compared to the industry in which it operates. Mereo BioPharma Group plc (MREO) shares have gone up 58.22% during the last six months, with a year-to-date growth rate more than the industry average at 91.89% against 11.40.
Mereo BioPharma Group plc is due to release its next quarterly earnings on March 28. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mereo BioPharma Group plc (NASDAQ:MREO)’s Major holders
Mereo BioPharma Group plc insiders own 0.00% of total outstanding shares while institutional holders control 51.68%, with the float percentage being 51.68%. Rubric Capital Management LP is the largest shareholder of the company, while 74 institutions own stock in it. As of Mar 30, 2023, the company held over 10.37 million shares (or 15.30% of all shares), a total value of $11.71 million in shares.
The next largest institutional holding, with 7.75 million shares, is of Orbimed Advisors LLC.’s that is approximately 11.44% of outstanding shares. At the market price on Mar 30, 2023, these shares were valued at $8.76 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mereo BioPharma Group plc (MREO) shares are Tekla Healthcare Investors and Tekla Life Sciences Investors. Data provided on Dec 30, 2022 indicates that Tekla Healthcare Investors owns about 1.06 million shares. This amounts to just over 1.57 percent of the company’s overall shares, with a $1.2 million market value. The same data shows that the other fund manager holds slightly less at 0.49 million, or about 0.72% of the stock, which is worth about $0.55 million.